Nancy Lewis

4.1k total citations · 1 hit paper
62 papers, 2.9k citations indexed

About

Nancy Lewis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Nancy Lewis has authored 62 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Nancy Lewis's work include Colorectal Cancer Treatments and Studies (10 papers), Cancer Treatment and Pharmacology (7 papers) and Colorectal Cancer Screening and Detection (6 papers). Nancy Lewis is often cited by papers focused on Colorectal Cancer Treatments and Studies (10 papers), Cancer Treatment and Pharmacology (7 papers) and Colorectal Cancer Screening and Detection (6 papers). Nancy Lewis collaborates with scholars based in United States, Canada and Germany. Nancy Lewis's co-authors include Roger B. Cohen, Louis M. Weiner, Neal J. Meropol, Neal J. Meropol, Richard C. Veith, Lia Gore, Sami Diab, E. Gabriela Chiorean, Cindy L. O’Bryant and Laura Q.M. Chow and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Biological Psychiatry.

In The Last Decade

Nancy Lewis

62 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

2021 240 citations Funda Meric‐Bernstam, Randy F. Sweis et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nancy Lewis United States	29	1.5k	875	811	516	354	62	2.9k
Rebecca Slack United States	32	1.5k 1.0×	1.0k 1.2×	846 1.0×	590 1.1×	628 1.8×	101	3.8k
Luís Teixeira France	28	1.1k 0.7×	604 0.7×	698 0.9×	585 1.1×	451 1.3×	93	3.3k
Cornelius F. Waller Germany	31	1.0k 0.7×	867 1.0×	419 0.5×	486 0.9×	171 0.5×	158	3.2k
Ping Jiang China	29	1.3k 0.9×	669 0.8×	359 0.4×	493 1.0×	477 1.3×	133	3.4k
Luca Fumagalli Italy	25	1.4k 0.9×	370 0.4×	491 0.6×	559 1.1×	528 1.5×	122	2.6k
Emily L. Bellile United States	30	1.0k 0.7×	729 0.8×	446 0.5×	463 0.9×	462 1.3×	106	2.6k
Thomas Cerny Switzerland	25	921 0.6×	568 0.6×	477 0.6×	248 0.5×	233 0.7×	53	2.2k
Sun‐Young Kong South Korea	32	1.3k 0.9×	1.4k 1.6×	498 0.6×	373 0.7×	683 1.9×	204	3.7k
Fengmin Zhao United States	29	2.0k 1.3×	745 0.9×	752 0.9×	402 0.8×	607 1.7×	77	3.0k

Countries citing papers authored by Nancy Lewis

Since Specialization

Citations

This map shows the geographic impact of Nancy Lewis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy Lewis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy Lewis more than expected).

Fields of papers citing papers by Nancy Lewis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy Lewis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy Lewis. The network helps show where Nancy Lewis may publish in the future.

Co-authorship network of co-authors of Nancy Lewis

This figure shows the co-authorship network connecting the top 25 collaborators of Nancy Lewis. A scholar is included among the top collaborators of Nancy Lewis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nancy Lewis. Nancy Lewis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garralda, Elena, Takafumi Koyama, Paolo A. Ascierto, et al.. (2023). 695P A phase I/Ib study evaluating the safety and tolerability of NIZ985 alone and in combination with spartalizumab (anti–PD-1) in patients (pts) with solid tumors or lymphoma. Annals of Oncology. 34. S484–S484. 3 indexed citations

Leidner, Rom S., Kevin C. Conlon, Douglas G. McNeel, et al.. (2023). First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors. Journal for ImmunoTherapy of Cancer. 11(10). e007725–e007725. 14 indexed citations

Meric‐Bernstam, Funda, Randy F. Sweis, F. Stephen Hodi, et al.. (2021). Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research. 28(4). 677–688. 240 indexed citations breakdown →

Javle, Milind, Robin Kate Kelley, Sameek Roychowdhury, et al.. (2018). Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. Annals of Oncology. 29. viii720–viii720. 33 indexed citations

Yoon, Harry H., Johanna C. Bendell, Fadi S. Braiteh, et al.. (2016). Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Annals of Oncology. 27(12). 2196–2203. 98 indexed citations

Agarwal, Neeraj, Jean-Pascal Machiels, Cristina Suárez, et al.. (2016). Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer. The Oncologist. 21(5). 535–536i. 48 indexed citations

Denlinger, Crystal S., Neal J. Meropol, Tianyu Li, et al.. (2014). A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Biliary Tract Cancers. Clinical Colorectal Cancer. 13(2). 81–86. 25 indexed citations

Marshall, John L., Jimmy Hwang, Ferry A.L.M. Eskens, et al.. (2012). A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Investigational New Drugs. 31(2). 399–408. 39 indexed citations

Tsimberidou, Apostolia M., Nancy Lewis, Tony Reid, et al.. (2011). Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 68(6). 1507–1516. 6 indexed citations

10.

Brouwers, Melissa, June Carroll, Michelle Cotterchio, et al.. (2011). What implementation interventions increase cancer screening rates? a systematic review. Implementation Science. 6(1). 111–111. 107 indexed citations

11.

Cohen, Steven J., Paul F. Engstrom, Nancy Lewis, et al.. (2008). Phase I Study of Capecitabine and Oxaliplatin in Combination With the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors. American Journal of Clinical Oncology. 31(1). 1–5. 12 indexed citations

12.

Šikić, Branimir I., Heather A. Wakelee, Margaret von Mehren, et al.. (2007). A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI.. Molecular Cancer Therapeutics. 6. 33 indexed citations

13.

Lewis, Nancy. (2007). The platelet-derived growth factor receptor as a therapeutic target. Current Oncology Reports. 9(2). 89–95. 10 indexed citations

14.

Stadler, Walter M., Apurva A. Desai, David I. Quinn, et al.. (2007). A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemotherapy and Pharmacology. 61(4). 689–694. 22 indexed citations

15.

Cohen, Steven J., R. Katherine Alpaugh, Steve Gross, et al.. (2006). Isolation and Characterization of Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 6(2). 125–132. 157 indexed citations

16.

Kimmel, Kathryn A., James M. Gallo, G. R. Hudes, et al.. (2006). Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours. British Journal of Cancer. 94(11). 1621–1626. 146 indexed citations

17.

Lewis, Nancy, et al.. (2004). Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients. Bone Marrow Transplantation. 33(1). 71–78. 18 indexed citations

18.

Lewis, Nancy, Richard M. Scher, James M. Gallo, et al.. (2002). Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed. Cancer Chemotherapy and Pharmacology. 50(4). 257–265. 5 indexed citations

19.

Lewis, Nancy & Neal J. Meropol. (2000). Oral Fluoropyrimidines in Cancer Treatment. Cancer Investigation. 18(8). 747–760. 9 indexed citations

20.

Lewis, Nancy, et al.. (1989). Preliminary evidence of benzodiazepine subsensitivity in panic disorder. Biological Psychiatry. 26(7). 744–748. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact